Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Glycomimetics for the inhibition and modulation of lectins
Steffen Leusmann, Petra Ménová, Elena Shanina, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 11, pp. 3663-3740
Open Access | Times Cited: 57
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine
Sijun Pan, Aixiang Ding, Yisi Li, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 16, pp. 5706-5743
Closed Access | Times Cited: 30
Selenium Nanodots (SENDs) as Antioxidants and Antioxidant‐Prodrugs to Rescue Islet β Cells in Type 2 Diabetes Mellitus by Restoring Mitophagy and Alleviating Endoplasmic Reticulum Stress
Qiong Huang, Zerun Liu, Yunrong Yang, et al.
Advanced Science (2023) Vol. 10, Iss. 19
Open Access | Times Cited: 28
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 22
A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation
Yangyang Huang, Xujiao Zhou, Yirou Zhang, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 10
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Siqi Wang, Fuchu He, Chunyan Tian, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 100-100
Open Access | Times Cited: 9
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 10, pp. 4838-4861
Closed Access | Times Cited: 9
Long non‐coding RNAs as key regulators of neurodegenerative protein aggregation
Qi Xu, Dan Liu, Ling‐Qiang Zhu, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
HDAC4 in cancer: A multitasking platform to drive not only epigenetic modifications
Emma Cuttini, Camilla Goi, Ester Pellarin, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 17
Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs
Yanping Zeng, Jian Xiao, Yuanxin Xu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 12877-12893
Closed Access | Times Cited: 17
Inhibitors to degraders: Changing paradigm in drug discovery
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 7
Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects
Shuixia Tan, Da Wang, Yuhua Fu, et al.
Science Bulletin (2023) Vol. 68, Iss. 23, pp. 3013-3026
Open Access | Times Cited: 15
Targeting mitochondrial degradation by chimeric autophagy-tethering compounds
Zhenqi Liu, Geng Qin, Jie Yang, et al.
Chemical Science (2023) Vol. 14, Iss. 40, pp. 11192-11202
Open Access | Times Cited: 14
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
Yu Ding, Dong Xing, Yiyan Fei, et al.
Medicine Plus (2024) Vol. 1, Iss. 1, pp. 100004-100004
Open Access | Times Cited: 5
Targeting EGFR degradation by autophagosome degraders
ZhongFeng Zhu, Jiaying Li, Shujun Shen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116345-116345
Closed Access | Times Cited: 5
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Receptor-ligand interactions for optimized endocytosis in targeted therapies
Yejin Sung, Young‐Jin Choi, Eun Sun Kim, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 524-538
Open Access
Systematic evolution of functional oligonucleotides for targeted protein degradation
Huang Su, Yifan Chen, Xuyang Zhao, et al.
Chem (2025), pp. 102408-102408
Closed Access
Page 1 - Next Page

Scroll to top